8-K: Connect Biopharma Asthma Study Shows Promising Lung Function Improvement

Connect Biopharma announced positive topline results from its Phase 2 asthma study, showing rademikibart significantly improved lung function and reduced treatment failures, though the primary endpoint missed statistical significance.

Summary

• Connect Biopharma announced topline results from its global Phase 2 study of rademikibart for acute exacerbations in adult and adolescent asthma patients with type 2 inflammation.
• The study evaluated rademikibart as an add-on treatment to standard of care in 160 patients.
• Rademikibart demonstrated a statistically significant increase in post-bronchodilator FEV1 on Day 7 (250 mL vs. 120 mL for placebo, p=0.023).
• The treatment failure rate was reduced by approximately 66% over 28 days compared to placebo (p=0.153), though this primary endpoint did not reach statistical significance due to a lower-than-projected overall treatment failure rate.
• A 50% reduction in emergency department visits or unscheduled medical visits for worsening asthma symptoms was observed compared to placebo.
• Rademikibart was well-tolerated with a safety profile comparable to placebo, with no new safety signals and a low incidence of adverse events.
• The company plans to meet with the FDA to align on a Phase 3 program and expects topline data from its COPD study later this month.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a cautiously optimistic development. While the primary endpoint did not reach statistical significance, key secondary endpoints showed strong positive results and the drug was well-tolerated, suggesting potential for future success.

Positives

• Statistically significant improvement in post-bronchodilator FEV1 on Day 7 (250 mL vs. 120 mL for placebo, p=0.023), indicating rapid lung function recovery.
• A substantial 66% reduction in the treatment failure rate over 28 days compared to placebo, demonstrating a strong clinical effect.
• A 50% reduction in emergency department visits or unscheduled medical visits for worsening asthma symptoms.
• Rademikibart was well-tolerated with a safety profile comparable to placebo, with no new safety signals observed.
• Low incidence of adverse events (AEs) and serious adverse events (SAEs) in the rademikibart arm (1 SAE vs. 3 in placebo).
• The Day 7 FEV1 improvement is a key secondary endpoint that the company plans to propose to the FDA as a Phase 3 endpoint, aligning with FDA preference for rapid benefit.
• The company is advancing towards a Phase 3 program and expects COPD study data soon.

Negatives

• The primary endpoint of treatment failure rate over 28 days did not reach statistical significance (p=0.153) due to a lower-than-projected overall treatment failure rate in the study.
• The study was powered based on a projected 45% placebo arm TxF rate and a ~50% reduction for the benralizumab arm in a prior study (ABRA), whereas the actual placebo arm TxF rate was 7.4% and the rademikibart arm TxF rate was 2.5%.

Risks

• The primary endpoint for treatment failure did not achieve statistical significance, which could impact regulatory approval and market perception.
• The company's ability to demonstrate safety and efficacy in future trials, including Phase 3.
• Obtaining and maintaining regulatory approval for rademikibart.
• Market acceptance of rademikibart by physicians, patients, and healthcare payors.
• Potential for adverse global macroeconomic and geopolitical conditions to impact the business.
• Reliance on third parties for clinical trials and manufacturing.
• Intellectual property protection and enforcement.

Future Outlook

Connect Biopharma plans to meet with the FDA to align on a Phase 3 program for rademikibart for acute exacerbations of asthma and COPD. Topline data from the Phase 2 Seabreeze STAT COPD study is expected later this month. The company aims to leverage the Phase 2 asthma study results, particularly the rapid FEV1 improvement, as a proposed primary endpoint for Phase 3 trials.

Management Comments

• "Today's data highlight the statistically significant rapid improvements in FEV1 within one week post treatment as well as a 66% reduction in treatment failures at 28 days, although that endpoint did not reach statistical significance."
• "The overall results of this study provide a clear roadmap for design of a Phase 3 program."
• "Taken together with updated market research showing approximately 1.6M ED visits in 2025 for acute asthma exacerbation by high-T2 patients, we believe these results support the potential of rademikibart to deliver significant patient impact and reduce the health economic burden for patients and hospitals."
• "66% reduction in treatment failure is an exceptional outcome and is particularly impressive and shows a meaningful improvement over standard-of-care therapy alone."
• "The ability to deliver this magnitude of benefit while also significantly improving lung function underscores the potential of rademikibart to improve outcomes and establish a new treatment paradigm for managing acute exacerbations in the hospital setting."

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry is highly competitive, with significant investment in developing novel treatments for inflammatory diseases like asthma and COPD. The focus on IL-4R alpha antibodies places rademikibart in a category with existing therapies, but its potential as a 'next-generation, potentially best-in-class' agent for acute exacerbations, if proven in Phase 3, could carve out a significant market niche.

Comparison to Industry Standards

• The study's primary endpoint, treatment failure, is a composite measure including death, hospital admission, ED visits, or intensification of treatment. This is a common approach in asthma exacerbation trials.
• The key secondary endpoint, change in FEV1, is a standard measure of lung function and a frequently used endpoint in asthma clinical trials.
• The observed 66% reduction in treatment failure, while not statistically significant, is a substantial magnitude of effect compared to placebo, and the 50% greater reduction than projected suggests a strong signal.
• The 1.6 million ED visits for acute asthma attacks in T2 high patients in the US in 2025, as cited from Komodo Health data, highlights the significant unmet need and market opportunity.
• The low penetration of biologics (2.26% of all asthma patients, 3.44% in T2 high subset) indicates a large, underserved market for effective treatments.

Stakeholder Impact

• Shareholders: The results, while mixed, suggest potential for a valuable drug candidate, but the missed primary endpoint may temper immediate enthusiasm and could impact stock price pending further clarity on Phase 3 plans.
• Patients: Positive safety profile and significant improvements in lung function and reduction in treatment failures (though not statistically significant for the primary endpoint) offer hope for better management of acute asthma exacerbations.
• Healthcare Providers: The data suggests rademikibart could be a valuable addition to the standard of care for managing acute asthma exacerbations, potentially reducing hospitalizations and ED visits.
• Payors: A reduction in treatment failures and ED visits could lead to cost savings for healthcare systems.

Next Steps

• Report topline data from the ongoing Phase 2 Seabreeze STAT COPD study later this month.
• Meet with the U.S. Food and Drug Administration (FDA) to gain alignment on a Phase 3 program for rademikibart.
• Propose the Day 7 FEV1 improvement as a primary endpoint for Phase 3 trials.
• Continue to develop rademikibart for acute exacerbations of asthma and COPD.

Key Dates

Recommendation

The mixed results, with a statistically significant secondary endpoint and strong numerical results on the primary endpoint, coupled with a favorable safety profile, warrant a 'hold' recommendation. While promising, the missed primary endpoint introduces uncertainty regarding regulatory approval and commercial success. Further clarity on the Phase 3 program and its design will be crucial for a more definitive recommendation.

Keywords

rademikibart, asthma, acute exacerbations, type 2 inflammation, Phase 2 study, FEV1, treatment failure, biopharmaceutical